Clinical Trials Logo

Urinary Bladder, Overactive clinical trials

View clinical trials related to Urinary Bladder, Overactive.

Filter by:

NCT ID: NCT04120545 Completed - Clinical trials for Urinary Incontinence

Effectiveness of Microcurrents Therapy in Overactive Bladder.

Start date: November 4, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect on the overactive bladder in women using a care protocol plus the application of microcurrent patches during 1 hours per session compared to the effect of the same protocol plus placebo electric stimulation.

NCT ID: NCT04115228 Completed - Overactive Bladder Clinical Trials

Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)

Start date: October 9, 2019
Phase: N/A
Study type: Interventional

Study objectives: To report feasibility data for safety and effectiveness of the study device. Study device: Nine Continents Medical implantable tibial nerve stimulator (ITNS) model 9C-680 with programmer model 9C-580. Intended use: The study device is intended for treatment of the symptoms of overactive bladder (OAB), including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments. Type of design: Single-arm longitudinal design. Study sites: Single site, in the United States. Study duration: One year total, comprising six months for enrolling and implanting 10 subjects, and 26 weeks for follow-up.

NCT ID: NCT04113941 Active, not recruiting - Overactive Bladder Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder

Start date: August 23, 2019
Phase: Phase 3
Study type: Interventional

This study is for patients who have idiopathic overactive bladder symptoms. This study will evaluate efficacy and safety of Neuronox® against placebo.

NCT ID: NCT04103450 Completed - Overactive Bladder Clinical Trials

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Start date: September 19, 2019
Phase: Phase 3
Study type: Interventional

This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).

NCT ID: NCT04075578 Recruiting - Bladder, Overactive Clinical Trials

Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)

TOX50IUU
Start date: June 26, 2019
Phase:
Study type: Observational

Considering that the 2013 Hermieu's guidelines differs from the product marketing authorization delivered in November 2014, the primary endpoints is to evaluate life quality by questionnaires at the baseline time, and after two, six and twelve weeks of treatment in patients suffer from urinary incontinence by refractory idiopathic overactive bladder and treated by Botox® at the dose of 50UI (international units)

NCT ID: NCT04068025 Completed - Quality of Life Clinical Trials

Information, Motivation, Behavioral Skills Model on Urinary Incontinence and Quality of Life in Men

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

Multiple studies have shown that education based on the IMB model is effective at bringing about health-related behavior change. The IMB model was found to be effective in developing healthy behaviors aimed at maintaining heart health, providing behavior to prevent smoking addiction, diabetes management, correct nutrition in iron deficiency anemia, and using condoms to prevent HIV. There are no studies in the literature regarding the adaptation of the IMB model to behavioral therapy in patients with OAB or urinary incontinence. To address this, there we aimed to investigate the effect of the IMB model on urinary incontinence and quality of life in men with OAB.

NCT ID: NCT04063852 Completed - Multiple Sclerosis Clinical Trials

PTNS on Urinary and Global Quality of Life in MS Patients

PTNSinMS
Start date: February 27, 2019
Phase:
Study type: Observational

This is a single-centered, prospective, longitudinal, observational cohort study of patients with MS who suffer from lower urinary tract symptoms (LUTS) and are refractory to two prior treatment modalities who have elected to pursue PTNS therapy for LUTS.

NCT ID: NCT04059133 Recruiting - Overactive Bladder Clinical Trials

The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder

Start date: February 27, 2018
Phase: N/A
Study type: Interventional

The hypothesis of the present study is low intensity extracorporeal low energy shock wave therapy (LiESWT) can decrease inflammatory disorders, increase pelvic floor blood supply, enhanced bladder stem cell activation, Using LiESWT can decrease bladder overactivity, eliminate urinary incontinence and improve stress urinary incontinence (SUI) and overactive bladder (OAB) symptoms. Therefore improve quality of life and improve social activity.

NCT ID: NCT04031014 Recruiting - Overactive Bladder Clinical Trials

High Intensity Focused Electromagnetic Field Device for Urinary Incontinence

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercise over 28 minutes, with the intention of increasing neuromuscular tone of the pelvic floor. This study will have looking at treatment of the two of the most common pelvic floor disorders: stress or stress predominant urinary incontinence and urge or urge predominant urinary incontinence.

NCT ID: NCT04023253 Recruiting - Clinical trials for Overactive Bladder Syndrome

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Start date: August 1, 2019
Phase: Phase 3
Study type: Interventional

To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and bladder blood flow.